All In Biotech

Drug Trial Radar · NCT06145373

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

An Open-label, Single-arm Treatment Study to Investigate the Safety and Tolerability of Switching From Emicizumab to Fitusiran Prophylaxis in Male Participants Aged ≥12 Years of Age With Severe Hemophilia A, With or Without Inhibitors

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Mar 1, 2024

Primary completion

May 28, 2028

Study completion Jan 30, 2030

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an exploratory, single group, Phase 4, study to assess treatment with fitusiran prophylaxis after switching from emicizumab prophylaxis. This study aims to evaluate the safety and tolerability of switching to fitusiran after a transition period from the last dose of emicizumab. The study will be conducted in male participants with severe hemophilia A, with or without inhibitors, aged ≥12 years, who were previously receiving emicizumab prophylaxis. Study details include: * The study duration will be up to approximately 28 months: * There will be an approximately 2-month screening period. * There will be an approximately 2-month period before fitusiran treatment starts (pre-fitusiran treatment period) * The fitusiran treatment duration will be up to 18-months (fitusiran treatment period) * The antithrombin (AT) follow-up (FU) period will be approximately 6 months after the last dose of fitusiran (during which the AT activity level will be monitored at approximately monthly intervals following the final fitusiran dose until AT activity levels return to at least 60%). * The study site visits are scheduled at monthly/ every 2 months intervals of 28 days (4 weeks) / 56 days (8 weeks), respectively, during the fitusiran treatment period.

Conditions

  • Hemophilia A

Interventions

  • Fitusiran (SAR439774)Drug

    Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous (SC) injection

  • Clotting factor concentrates (CFC) or bypassing agents (BPA)Biological

    Pharmaceutical form: Solution for injection-Route of administration: Intravenous (IV) injection

  • Antithrombin concentrate (ATIIIC)Biological

    Pharmaceutical form:Solution for injection-Route of administration:Intravenous (IV) injection

  • EmicizumabBiological

    Pharmaceutical form:Solution for injection-Route of administration:SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse events (AEs) during the fitusiran treatmentTime frame: From Day 1 up to Month 4

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles- Site Number : 8400005

    Los Angeles, California · Recruiting

  • Southern Specialty Research- Site Number : 8400011

    Flowood, Mississippi · Recruiting

  • Investigational Site Number : 1580001

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.